69321-18-2 Usage
General Description
The chemical 3-[(E)-(4-aminophenyl)diazenyl]phenylmethanol is also known as Sudan IV, and is a synthetic azo dye. It is commonly used as a lipid-soluble dye for the staining of lipids, waxes, and triglycerides. It has a deep red color and is often used in a variety of industries, including histology and pathology. Sudan IV has also been used as a color additive in some products, although its use in food and cosmetic products has been restricted in some regions due to potential health concerns. The chemical structure of Sudan IV includes an azo group, a phenyl ring, and a hydroxyl group, making it suitable for a variety of applications in the laboratory and industrial settings.
Check Digit Verification of cas no
The CAS Registry Mumber 69321-18-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,9,3,2 and 1 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 69321-18:
(7*6)+(6*9)+(5*3)+(4*2)+(3*1)+(2*1)+(1*8)=132
132 % 10 = 2
So 69321-18-2 is a valid CAS Registry Number.
69321-18-2Relevant articles and documents
Low-oxygen dual-targeting AGT inhibitor conjugate, and preparation method and application thereof
-
Paragraph 0074-0079; 0122-0127, (2020/08/09)
The invention relates to the field of medicine preparation, and in particular relates to a low-oxygen dual-targeting AGT inhibitor conjugate, and a preparation method and application thereof. The low-oxygen dual-targeting AGT inhibitor conjugate comprises an AGT inhibitor and a hydrophilic high polymer material, wherein the AGT inhibitor is coupled through low-oxygen responsive groups, and the hydrophilic high polymer material is specifically combined with a CD44 receptor overexpressed on the surfaces of tumor cells. The amphiphilic low-oxygen dual-targeting AGT inhibitor conjugate can form anano-carrier through self-assembly, is used for encapsulating an anti-tumor drug and delivering the anti-tumor drug to a tumor region in a targeting manner, and releases the drug in a low-oxygen environment, so that a targeting anti-tumor effect is achieved, and meanwhile, drug resistance and good water solubility are achieved simultaneously.
